|
|
 |
|
Viewing report
|
|
|
|
The Respiratory Disease Pipeline: A Competitive Review
Decision Resources, Inc, Sep 2011
Despite the availability of a plethora of symptomatic treatments, many common chronic respiratory diseases - such as asthma and chronic obstructive pulmonary disorder (COPD) - lack curative therapies or therapies that can reverse disease progression. As part of this analysis of these and other unmet needs in the respiratory disease therapeutic area, 117 respiratory agents have been confirmed in active clinical development. This report examines the respiratory disease pipeline, the companies involved in the development of these agents, and the opinions of 105 surveyed pulmonologists and primary care physicians (PCPs) regarding the current and future respiratory disease drug market.
Questions answered in this report:
- Asthma and COPD are two of the respiratory diseases with the largest numbers of prevalent cases in the major markets that we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). How do these prevalence numbers correspond to the number of patients with respiratory diseases who are treated or monitored by surveyed physicians in a typical 30-day period?
- The respiratory disease pipeline comprises agents with both familiar and novel mechanisms of action/targets as well as a mix of small-molecule drugs and biologics. What novel targets/mechanisms of action is the respiratory disease pipeline focused on, and what is the breakdown of small-molecule drugs versus biologics in the pipeline?
- Large-cap pharmaceutical companies lead the respiratory disease pipeline in terms of numbers of agents in clinical development. Which large-cap companies' respiratory disease pipelines are the largest? Are they the same companies that currently dominate the respiratory disease market?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Survey of 105 physicians—51 pulmonologists and 54 PCPs.
Emerging therapies: Phase I: 41 drugs; Phase II: 63 drugs; Phase III: 12 drugs; filed for approval: 1 drug.
|
|
|
|
